after a two-week placebo lead-in period , each patient received increasing doses of terazosin or prazosin at two-week intervals until the supine diastolic blood pressure was decreased by 7 mm hg or more compared with baseline , or until the maximum dose was reached .
C0076107
terazosin
C0032912
prazosin